|
|
|
News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. |
|
|
| June 11, 2013 | | 16:08 EDT |  | STJ | FDA approves St. Jude Medical devices with new safety features
St. Jude Medical announced FDA approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery. | | | June 10, 2013 | | 12:22 EDT |  | STJ | St. Jude's Durata backed by doctor who found Riata defect, Bloomberg says
 Subscribe for More Information | | | June 7, 2013 | | 11:05 EDT | | STJ | St. Jude invests $40M in Spinal Modulation, gets exclusive option to acquire
St. Jude Medical and privately-held Spinal Modulation announced that they have entered into a series of agreements under which St. Jude Medical made a $40M equity investment in Spinal Modulation, a company that has developed an innovative neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain. The agreement provides St. Jude Medical with an exclusive option to distribute the Axium Neurostimulator System, developed and manufactured by Spinal Modulation, in international markets where it is approved for sale. Additionally, St. Jude Medical will have the exclusive option to acquire the company for up to $300M plus certain revenue-based milestones following U.S. commercialization. | | | June 4, 2013 | | 11:58 EDT |  | STJ | Failure of St. Jude Medical Durata could be cause for concern, says Wells Fargo
Wells Fargo believes that the failure of a single Durata lead made by St. Jude could justify concerns about potential Durata failures. The firm notes, however, that the device short circuited, and that the company plans to unveil new leads that switch vectors in order to counter short circuits. The firm keeps a Market Perform rating on St. Jude. | | | 08:06 EDT | | STJ | St. Jude Medical initiates EnligHTN IV Renal Denervation Study
St. Jude Medical announced U.S. Food and Drug Administration approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure. The EnligHTN IV study is a randomized, single-blind, controlled, multi-center trial to demonstrate the safety and effectiveness of the EnligHTN Renal Denervation System in reducing systolic blood pressure when measured in an office setting. The study will enroll approximately 590 patients between the ages of 18 and 80 with an office systolic blood pressure of 160 mmHg or greater, who are taking three or more antihypertensive medications including a diuretic. Study patients will be enrolled at up to 80 sites in the U.S. and Canada. | |
|
|
|
|
|
|
